Activated protein C resistance: What have we learned now that the dust has settled?

Annals of Medicine

Volumn 29, Issue 6, 1997, Pages 469-472

  Petäjä, Jari M ^a   Griffin, John H ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ARGININE; BLOOD CLOTTING FACTOR 5; GLUTAMINE; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ARTERY THROMBOSIS; EDITORIAL; GENETIC VARIABILITY; HUMAN; POINT MUTATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VEIN THROMBOSIS;

EID: 0031419257     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899709007469     Document Type: Editorial

References (22)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
2. Dahlbäck B. Molecular genetics of venous thromboembolism. Ann Med 1995; 27: 187-92.
3. Leiden and thrombophilia. Arterioscler Thromb Vasc Biol 1997; 17: 620-7.
4. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
5. Greengard JS, Sun X, Xu X, Fernández JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-2.
6. 506 of factor V. Lancet 1994; 343: 1535-6.
7. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89: 397-402.
8. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
9. Simioni P, Pradoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an Arg506 to Gin mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-400.
10. Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1995; 75: 229-32.
11. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-6.
12. Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
13. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
14. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
15. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173; 210-3.
16. Bokarewa MI, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-8.
17. Halbmayer W-M, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5: 51-7.
18. 506→glutamine mutation. Stroke 1996; 27: 1163-6.
19. van der Bom JG, Bots ML, Haverkate F, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996; 125: 265-9.
20. Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb Res 1996; 82: 235-44.
21. Pötzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Müller-Berghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995; 125: 56-65.
22. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.